Navigation Links
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
Date:5/14/2012

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 – 5, 2012.

Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. The company remains committed to evaluating each of its molecules for biomarkers or genetic mutations that can help better identify the specific patients who will better respond to these medicines.  

Early-Stage Pipeline Results

Lilly early-stage pipeline molecules will be featured at oral presentations at ASCO with two first-in-human Phase I studies, one on its oral NOTCH inhibitor LY900009 and the other for its oral p38 MAPK inhibitor LY2228820 dimesylate, both being evaluated in patients with advanced cancer. Another oral presentation will highlight LY2780301, an oral P70S6K/AKT inhibitor, a first-in-human Phase I study of patients with refractory solid tumors.

Late-Stage Ramucirumab Updates

Lilly will also present several trials-in-progress posters representing a portion of the broad Phase III clinical development program for ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist designed to bind to the extracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). Trial updates for ramucirumab will focus on its ongoing Phase III trials in metastatic colorectal cancer, metastatic gastric adenocarcinoma and hepatocellular cancer, as well as results of a Phase II study in persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Ramucirumab represents one of the largest clinical programs currently underway at Lilly. Six global Phase III tria
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
2. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. DiversityInc Names Lilly a Top Company for Diversity
5. Lilly Declares Second-Quarter 2012 Dividend
6. Lilly Diabetes and Walgreens Launch Diabetes Hypoglycemia Awareness Campaign
7. Lillys John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts
8. Lilly Confirms Date and Conference Call for First-Quarter 2012 Financial Results Announcement
9. Lilly Diabetes supports Diabetes Scholars Foundation with $100,000 donation in 2012
10. Fifth Lilly Oncology on Canvas Art Competition Invites All Touched by Cancer to Share Their Cancer Journeys
11. Boehringer Ingelheim and Lillys new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
(Date:11/26/2014)... 26, 2014 Senior Planning Services, providing ... a nonprofit organization providing the adult demographic education ... help seniors navigate the rough seas of applying for ... seniors on the topic of Medicaid eligibility and proper ... process of applying for this coverage. , Senior ...
(Date:11/26/2014)... November 26, 2014 ISI Telemanagement ... solutions, has been award the 2014 Lync ... This award comes as a great honor to ... the Lync ecosystem. Specifically, ISI offers an integrated ... of Lync communication, including voice, video, Lync IM, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... November 26, 2014 Bunion Bootie, the ... prices in an early celebration of the early holiday ... being offered at the promotional price of $29.95 each ... in addition to any automatic discounts applied when buying ... Bootie website for complete details. It’s simple: purchasing ...
(Date:11/26/2014)... Louisiana (PRWEB) November 26, 2014 ... pain relief and specialists in minimally invasive spine ... Samer Shamieh into the rapidly growing provider network ... The addition coincides with the network’s continuing ... medical treatment for Louisiana residents who are suffering ...
Breaking Medicine News(10 mins):Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist Company, ... group practice, today announced that it continues to experience,favorable ... net,revenues to be in the range of $57 million ... range of $4.2 million to $4.6 million. Absent the,impact ...
... CEO Scott Kornhauser,announced the appointment of Bryan Hebert ... Hebert was a former consulting partner with,over 18 ... in the healthcare,industry., Mr. Hebert,s responsibilities will ... market share for Healthation. Prior to,joining Healthation, Mr. ...
... Men whose tumors recur after prostate cancer surgery are ... term if they undergo radiotherapy within two years of ... whose new tumors were growing fastest, according to results ... Hopkins Medical Institutions researchers reported June 18 in the ...
... in DNA, study finds, , , TUESDAY, June 17 (HealthDay ... when it comes to cancer risk, according to a ... research suggests that stringent dietary changes, getting more exercise ... hundreds of genes. Some of the changes positively ...
... HILL, N.C., June 17 Across industry sectors,sales ... common operational, strategic and time management practices,according to ... LLC., The study shows the client still ... spend 21 percent of their time,building solutions for ...
... the death rate and might need to be used ... News) -- Countering common medical theory, a new study ... many men whose prostate cancer recurs aggressively after surgery. ... that recurs after surgery seem to benefit from salvage ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 2Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 3Health News:IPC The Hospitalist Company, Inc. Provides Second Quarter 2008 Outlook 4Health News:Radiation therapy prolongs life in men with recurrent prostate cancer 2Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3Health News:High-Performing Sales Forces Share Key Practices to Achieve Optimal Performance 2Health News:Radiation May Help When Prostate Cancer Returns 2Health News:Radiation May Help When Prostate Cancer Returns 3
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: